24/7 Market News- Azitra Granted and Allowed New Patents to Strengthen Global IP Portfolio

July 23, 2024

DENVER, Colo., Jul 23, 2024 (247marketnews.com)- Azitra, Inc. (NYSE:AZTR) stated that the U.S. Patent and Trademark Office (USPTO) granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled “Therapeutic treatment of skin disease with recombinant skin microorganisms.”

Furthermore, Azitra was allowed additional new patents in the U.S., Canada, and China:

Azitra’s COO, co-founder, and patents inventor, Travis Whitfill, commented, “We are delighted to announce our second US patent issuance this year and three additional patent allowances in key markets in the U.S., Canada, and China. The indication addressed by the newly issued U.S. patent, atopic dermatitis, affects approximately 16.5 million people in the United States. There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (AZTR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.